SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,589,443 with 63,351,197,653 in circulation. The last known price of XRP is 1.24455819 USD and is down -0.63 over the last 24 hours. It is currently trading on 1893 active market(s) with $917,900,293.08 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is under pressure amid a broader crypto selloff linked by traders to the Binance hack, while Ripples Swell announcements have drawn disappointment over the tokens muted response. The main debate is whether Ripples partnerships, bank charter and RLUSD growth will create demand for XRP, or primarily benefit Ripple and its stablecoin instead.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is dominated by the midterm elections and Trumps political fortunes, with traders debating how the outcome could affect DJT and broader markets; speculation over Iran-war escalation and oil prices adds to the uncertainty. Sentiment is mostly bearish, with posts citing DJTs sharp decline and weak fundamentals, though some traders anticipate a rebound.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats

VTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?

Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?

Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Natera Gains 118.1% in a Year: What's Driving the Rally?

NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.

Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms

VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.

Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.

Is it the Right Time to Add Phibro Stock to Your Portfolio?

PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Veracyte Inc

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Wood trimmed major recent winners, selling about $18 million of TWST along with smaller positions in TXG and CDNA.</li><li>RXRX has a 12-month consensus price target of $7.22, according to Koyfin, implying an upside potential of more than 51% from current levels.</li><li>Intellia is awaiting FDA review of its lead therapy for hereditary angioedema, with PDUFA date on March 10, 2027.</li></ul>Cathie Wood’s ARK Invest reshuffled its biotech holdings, buying several stocks that posted strong gains on Monday while trimming some of the sector’s biggest recent winners.Across&nbsp;<a href="https://stocktwits.com/symbol/ARKG">ARK Genomic Revolution ETF (ARKG)</a> and flagship&nbsp;<a href="https://stocktwits.com/symbol/ARKK">ARK Innovation ETF (ARKK)</a>, Wood bought about 1.48 million shares of Recursion Pharmaceuticals (RXRX), 96,308 shares of Intellia Therapeutics (NTLA), and 115,472 shares of Veracyte (VCYT), worth about $6.1 million, $1.2 million, and $5.3 million, respectively.Meanwhile, ARK sold 90,713 Twist Bioscience (TWST) shares worth $18 million, alongside smaller sales of 10x Genomics (TXG) and CareDx (CDNA).<h2 class="st-heading-2">What RXRX, NTLA And VCYT Have On Offer</h2><a href="https://stocktwits.com/symbol/RXRX">RXRX shares</a> surged more than 16% on Monday, and while there was no immediate trigger for the move, the AI drug-discovery company recently extended its data-licensing partnership with Tempus through 2029.The stock has a 12-month consensus price target of $7.22, according to Koyfin, implying an upside potential of more than 51% from current levels.<a href="https://stocktwits.com/symbol/NTLA">NTLA shares</a> closed 4% higher in the previous session, but the stock is currently down 2%. Intellia is awaiting U.S. Food and Drug Administration (FDA) review of its lead therapy for hereditary angioedema, with March 10, 2027, penciled in as the decision date.While NTLA shares have seen strong buying interest so far this year, surging more than 38%, Barclays believes the stock is likely to see a significant selloff. The firm initiated coverage with an ‘Underweight’ rating and an $8 price target, implying a 36% downside from current levels.Wood continued to build her <a href="https://stocktwits.com/symbol/VCYT">VCYT</a> position after adding roughly 159,000 shares earlier this month. Late last month, Veracyte said Phase 3 data showed its Decipher Prostate test could help identify which intermediate-risk prostate cancer patients may benefit from adding hormone therapy to radiation.According to Street estimates, the stock could climb at least 21% from current levels.&nbsp;&nbsp;<h2 class="st-heading-2">ARK Sells TWST, TXG, CDNA Despite Massive Moves</h2>ARK continued to unload <a class="mention" data-mention="$TWST" data-symbol-id="TWST" href="https://stocktwits.com/symbol/TWST" target="_blank">TWST shares</a> despite a sharp rally over the past month. TWST surged 8.7% on Monday and has added more than 60% to its value over the past month amid momentum around its synthetic-DNA platform and its agreement to support Eli Lilly’s TuneLab AI drug-discovery platform. Over the past few weeks, ARKG has unloaded TWST shares worth around $6 million.Meanwhile, TXG shares, which climbed 4.5% on Monday, have surged more than 48% in the past month, while <a href="https://stocktwits.com/symbol/CDNA">CDNA rose</a> 4% to its highest level in more than four years on Monday.<h2 class="st-heading-2">Retail’s Take On ARK’s Biotech Portfolio</h2>Retail sentiment on Stocktwits was bullish for TXG, NTLA, CDNA, and RXRX, bearish for VCYT, and neutral for TWST.<img src="https://news.stocktwits-cdn.com/ARK_YTD_8c95bdf841.png" alt="ARK YTD.png">Twist Bioscience and 10x Genomics have been the standout performers so far this year, up about 533% and 499%, respectively, while CareDx has gained roughly 265%, and NTLA, RXRX, and VCYT have posted double-digit advances.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/redwire-ceo-sees-massive-space-infrastructure-growth-ahead-compares-orbital-data-center-boom-to-rise-of-satellite-tv/cZDtb7wRBkY">Redwire CEO Sees ‘Massive’ Space Infrastructure Growth Ahead – Compares Orbital Data Center Boom To Rise Of Satellite TV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cathie Wood, CEO & Chief Investment Officer of ARK Invest, speaks onstage during Day 2 of 2023 Invest Fest at Georgia World Congress Center on August 27, 2023 in Atlanta, Georgia. (Photo by Paras Griffin/Getty Images)

Cathie Wood’s ARK Invest reshuffled its biotech holdings, buying several stocks that posted strong gains on Monday while trimming some of the sector’s biggest recent winners.

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.


BlackRock Senior High Income Fund, Inc.

ARK Investment Management LLC - ARK Genomic Revolution ETF

Caredx Inc

Intellia Therapeutics Inc

Recursion Pharmaceuticals Inc

Twist Bioscience Corp

10x Genomics Inc - Ordinary Shares - Class A

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$50.01
Prev Close	$52.17
Open	$51.54
Dividend Yield	0.00%
50-Day Moving Average	$44.42
Beta	1.44
Avg. Volume	1.44M
PE Ratio	35.48

52-Week High	$60.91
52-Week Low	$29.46
Market Capitalization	$4.02B
EPS (Annual)	$0.8235
Price to Book	2.89
Revenue Per Employee	$684,960.27

Feed

News

Sentiment

Earnings

Fundamentals

Info

VCYT Fundamentals